CMS’ GLP-1 Bridge Demonstration—Questions and Potential Consequences
Rachel E. Sachs, Kristi Martin
原始摘要（英文原文）· Original abstract
This Viewpoint discusses the US Centers for Medicare & Medicaid Services’ (CMS) extension of the Medicare Glucagon-Like Peptide-1 (GLP-1) Bridge and outlines unanswered questions related to how the bridge will affect Medicare.